Silexion Therapeutics (SLXN) announced new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation ...

The aggregate gross proceeds to the Company from the offering are expected to be $1.83 million, before deducting the placement agent fees and other offering expenses payable by the Company. The ...

The first siRNA drug, patisiran, was approved by the U.S. Food and Drug Administration (FDA) in 2018 to treat a debilitating genetic disorder called hereditary transthyretin amyloidosis.

The CTPA/siCSF1R system consists of a triblock polyamino acid (TPA) gene vector encapsulating siRNA, which is conjugated to the surface of photosynthetic cyanobacteria. It utilizes the inherent ...

Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo Programs to focus on silencing hard-to-drug targets of high therapeutic ...

你是否曾经担心过高血压对健康的威胁？作为全球范围内最常见的慢性疾病之一，高血压影响着数亿人的生活，它的隐秘性让我们常常无从察觉，直到一系列严重的健康问题出现。就在最近，华东医药与施能康的战略合作，开启了一条新的治疗之路，开发出一种新型小核酸药物SNK-2726，为高血压的应对方案注入了希望的曙光。 这款药物的靶点为血管紧张素原（Angiotensinogen，AGT），它在高血压的发病机制中起着重 ...

Through this existing collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation was used for SIL-204, Silexion’s next-generation siRNA candidate. This ...

The therapeutic candidate is under development for the treatment of liver fibrosis and KRAS-driven liver cancer. It is an antisense RNAi oligonucleotide delivered through lipid-nanoparticles and is ...

根据合作协议，华东医药和施能康将共同推进SNK-2726的开发至一定阶段。在此过程中，华东医药将获得独家选择权，并可在未来支付行权费以获得SNK-2726在大中华区的独家开发、注册、生产和商业化的权利。一旦华东医药行权，施能康将有权获得后续研发里程碑 ...

BPR-30221616注射液作为倍特药业自主研发的siRNA药物，通过靶向和沉默特定的mRNA，阻断野生型和变体转甲状腺素蛋白的产生，从而达到治疗ATTR的目的。